

Table S5. Incidence rates of CIN2+ among 343 participants followed for up to 5 years, assessed using different age cut-offs

HPV genotype ^a	Ages 21+ (n=343)			Ages 25+ (n=268)			Ages 30+ (n=173)		
	CIN2+ events	Person-months ^b	Incidence rate (95% CI) ^c	CIN2+ events	Person-months ^b	Incidence rate (95% CI) ^c	CIN2+ events	Person-months ^b	Incidence rate (95% CI) ^c
Total HPV-positive	22	8210	2.7 (1.8, 4.1)	16	6381	2.5 (1.6, 4.1)	13	4071	3.2 (1.9, 5.6)
High-risk HPV									
Any type	20	5972	3.4 (2.2, 5.3)	15	4636	3.3 (2.0, 5.5)	12	2747	4.5 (2.5, 7.8)
16 ^d	8	1027	8.3 (4.1, 16.6) ^e	5	688	7.6 (3.2, 18.3) ^e	4	388	11.1 (4.2, 29.6) ^e
18/45 ^d	2	1020	2.0 (0.5, 7.9)	2	930	2.2 (0.5, 8.7)	1	493	2.0 (0.3, 14.5)
31/33/35/52/58 ^d	8	2257	3.6 (1.8, 7.2)	8	1753	4.6 (2.3, 9.3)	6	1109	5.5 (2.5, 12.3)
39/51/56/59/68 ^d	8	2901	2.8 (1.4, 5.6)	6	2123	2.8 (1.3, 6.3)	4	1242	3.2 (1.2, 8.6)
18	2	633	3.2 (0.8, 12.9)	2	613	3.3 (0.8, 13.3)	1	379	2.6 (0.4, 18.8)
31	1	437	2.3 (0.3, 16.4)	1	298	3.4 (0.5, 24.1)	1	146	7.1 (1.0, 50.1)
33 ^f	2	265	7.8 (2.0, 31.3) ^e	2	227	9.2 (2.3, 36.7) ^e	1	221	4.7 (0.7, 33.0)
35	1	401	2.5 (0.4, 17.8)	1	265	3.8 (0.5, 27.0)	1	175	5.8 (0.8, 41.0)
39	3	712	4.3 (1.4, 13.3)	2	462	4.4 (1.1, 17.5)	1	251	4.0 (0.6, 28.5)
45	0	387	0.0 (0.0, 9.5)	0	317	0.0 (0.0, 11.6)	0	114	0.0 (0.0, 32.5)
51	3	918	3.3 (1.1, 10.3)	2	700	2.9 (0.7, 11.5)	2	501	4.0 (1.0, 16.1)
52	3	840	3.6 (1.2, 11.2)	3	728	4.2 (1.3, 13.0)	3	491	6.2 (2.0, 19.3)
56	1	578	1.7 (0.2, 12.3)	1	422	2.4 (0.3, 16.9)	1	305	3.3 (0.5, 23.4)
58	2	420	4.9 (1.2, 19.6) ^e	2	306	6.8 (1.7, 27.1) ^e	1	139	7.5 (1.1, 53.0) ^e
59	1	763	1.3 (0.2, 9.4)	1	669	1.5 (0.2, 10.7)	0	365	0.0 (0.0, 10.1)
68	1	466	2.2 (0.3, 15.3)	1	268	3.8 (0.5, 26.6)	1	51	20.2 (2.8, 143.3) ^e
Low-risk HPV only	2	2210	0.9 (0.2, 3.6)	1	1716	0.6 (0.1, 4.2)	1	1295	0.8 (0.1, 5.5)
HPV-negative	2	1106	1.8 (0.5, 7.3)	2	1046	1.9 (0.5, 7.7)	1	858	1.2 (0.2, 8.3)

^a Includes both single- and multiple-type HPV infections (ie, for multiple types, progression events count towards all individual types present at enrollment)

^b Sum of person-months for all participants in group infected with noted genotype at enrollment

^c Incidence rate per 1000 person-months (95% CI = 95% confidence interval); estimated with exponential accelerated failure time models for interval-censored data; for genotypes with zero events, estimated with Poisson exact method

^d HPV risk stratification groups from Demarco et al. (2020)

^e Highest three incidence rates by individual HPV type

^f N<10 participants "exposed" or infected with HPV type overall